Biocept GAAP EPS of -$1.89 misses by $0.84, revenue of $25.9M beats by $18.65M
- Biocept press release (NASDAQ:BIOC): FY GAAP EPS of -$1.89 misses by $0.84.
- Revenue of $25.9M (-57.6% Y/Y) beats by $18.65M.
- Biocept reported cash of $12.9 million as of December 31, 2022, compared with $28.9 million as of December 31, 2021.
- The number of commercial accessions delivered for 2022 and 2021 were 294,182 and 532,520, respectively.
Recommended For You
Comments (1)
can anyone tell me if their cnside cancer assay is based on gene sequencing or something unique? Who else is doing this blood biomarket type test? Also does it help with outcomes for patients? Thanks.